SPDL1 and melanoma: In a study by Oh et al., blood samples were obtained before and after ICIs treatment in 128 patients with advanced malignancies (inter alia melanoma, lung, and urothelial cancers), and an increase in sPD-L1 levels was detected after immunotherapy.